America's #1 Online Cigar Auction
first, best, biggest!

Last post 7 months ago by DrMaddVibe. 275 replies replies.
6 Pages<123456>
hydroxychloroquine is back on!
Jump to Bottom | Previous Topic | Next Topic
teedubbya Offline
#51 Posted: Tue, May 19 2020, 3:39 PM EST
Joined: 08-14-2003
Posts: 95,637
I wonder who is going to get the last word in. Poopy head or poopy pants.
Gene363 Offline
#52 Posted: Tue, May 19 2020, 3:46 PM EST
Joined: 01-24-2003
Posts: 30,815
teedubbya wrote:
I wonder who is going to get the last word in. Poopy head or poopy pants.



LOL LOL LOL
victor809 Offline
#53 Posted: Tue, May 19 2020, 3:48 PM EST
Joined: 10-14-2011
Posts: 23,866
teedubbya wrote:
You sometimes have to listen to what you find invalid to either change your mind or solidify that it is invalid. It's worthwhile to listen to hear some of the messaging that is sticking. And like in most cases its not 100% garbage. There are some valid points. The whole is mostly wrong but there are some valid points including some boneheaded moves by the government and the "experts". Typically those are the things they grab on to and extrapolate in to crazyness and justifying their view. Thats why the "experts" need to be more careful but arent always. Folks are looking for one mistake to call it all a mistake.


I see what you're doing. You're making an accurate statement to try to convince me to watch some idiots.

I've already watched how the uncertainty in science is twisted by people to allow them to use a grain of truth to run in a completely insane direction. I don't need to watch it multiple times.

victor809 Offline
#54 Posted: Tue, May 19 2020, 3:49 PM EST
Joined: 10-14-2011
Posts: 23,866
Gene363 wrote:
Weak, really really weak. LOL LOL LOL


I just call it like I see it. His message is yours. Just because you don't like something about him doesn't change his message.
Gene363 Offline
#55 Posted: Tue, May 19 2020, 4:11 PM EST
Joined: 01-24-2003
Posts: 30,815
victor809 wrote:
I just see it like I call it. His message is yours. Just because you don't like something about him doesn't change his message.


Fixed the first sentence for you.
victor809 Offline
#56 Posted: Tue, May 19 2020, 4:14 PM EST
Joined: 10-14-2011
Posts: 23,866
Gene363 wrote:
I'm an idiot.

Fixed your first sentence for you too.
HockeyDad Offline
#57 Posted: Tue, May 19 2020, 4:40 PM EST
Joined: 09-20-2000
Posts: 46,134
teedubbya wrote:
https://www.pnas.org/content/early/2020/05/12/2006874117

I found this interesting. Peer reviewed. Remember the size of the droplet factors in not just the size of the virus.



Peer reviewed is like having your classmate grade your test for you.
teedubbya Offline
#58 Posted: Tue, May 19 2020, 4:40 PM EST
Joined: 08-14-2003
Posts: 95,637
Menards just turned someone away for not wearing a mask. I thanked the guard for enforcing it right in front of the maskless inconsiderate moron.
HockeyDad Offline
#59 Posted: Tue, May 19 2020, 4:44 PM EST
Joined: 09-20-2000
Posts: 46,134
What the hell are you doing out at Menards?! You have preexisting conditions and should be home sheltered in place. FOGs.....sheeesh
teedubbya Offline
#60 Posted: Tue, May 19 2020, 4:47 PM EST
Joined: 08-14-2003
Posts: 95,637
Repairing the deadbolt on my front door. It’s a matter of weighing risk bs benefit. I can’t afford to move to altitude so I had to fix the lock.
DrMaddVibe Offline
#61 Posted: Tue, May 19 2020, 4:49 PM EST
Joined: 10-21-2000
Posts: 55,431
Typhoid Dubs strikes again!
teedubbya Offline
#62 Posted: Tue, May 19 2020, 4:52 PM EST
Joined: 08-14-2003
Posts: 95,637
That’s why I wear the mask.

I wish I was lucky enough to be an asymptotic carrier. I’d give it to no one.
delta1 Offline
#63 Posted: Tue, May 19 2020, 4:57 PM EST
Joined: 11-23-2011
Posts: 28,788
did any body else see what I saw?

"pnas.org" looks kinda like a male only porn site..............trustworthy?
victor809 Offline
#64 Posted: Tue, May 19 2020, 5:09 PM EST
Joined: 10-14-2011
Posts: 23,866
delta1 wrote:
did any body else see what I saw?

"pnas.org" looks kinda like a male only porn site..............trustworthy?


Hehe...
As amusing as the acronym is, PNAS is a very well respected institution
teedubbya Offline
#65 Posted: Tue, May 19 2020, 5:15 PM EST
Joined: 08-14-2003
Posts: 95,637
not my pnas
izonfire Offline
#66 Posted: Tue, May 19 2020, 6:53 PM EST
Joined: 12-09-2013
Posts: 8,647
HockeyDad wrote:
Peer reviewed is like having your classmate grade your test for you.

3rd grade level, if you want to compare TW to a valid "peer"...
teedubbya Offline
#67 Posted: Tue, May 19 2020, 8:56 PM EST
Joined: 08-14-2003
Posts: 95,637
Pfff.

I done graduated the 5th grade
victor809 Offline
#68 Posted: Wed, May 20 2020, 10:21 AM EST
Joined: 10-14-2011
Posts: 23,866
This is honestly some fuxking nonsense:
"WELL, I HAVE WORKED WITH DOCTORS. IF YOU LOOK AT THE ONE SURVEY, THE ONLY BAD SURVEY THEY WERE GIVING IT TO PEOPLE IN BAD SHAPE, THEY WERE VERY OLD, ALMOST DEAD. IT WAS A TRUMP ENEMY STATEMENT.’"

This idiot actually things that scientific research is done to thwart him.

delta1 Offline
#69 Posted: Wed, May 20 2020, 3:27 PM EST
Joined: 11-23-2011
Posts: 28,788
and he actually said something that was blatantly a lie and easily checked: "a lot of frontline doctors and nurses are taking this as a preventative"...

ummm....no....has anyone found even a "few"?


We're in the middle of a pandemic crisis and the POTUS is doing this craziness?

I'm beginning to think he doesn't really want the job anymore because how many people are actually going to vote for this snake oil salesman clown again?
teedubbya Offline
#70 Posted: Wed, May 20 2020, 3:43 PM EST
Joined: 08-14-2003
Posts: 95,637
Many in here alone
Sunoverbeach Offline
#71 Posted: Wed, May 20 2020, 3:46 PM EST
Joined: 08-11-2017
Posts: 14,665
Sanity. Logic. A presidential candidate craves not these things
Speyside Offline
#72 Posted: Wed, May 20 2020, 3:49 PM EST
Joined: 03-16-2015
Posts: 13,106
Don't you mean another blatant lie? He's good for a few every day.
delta1 Offline
#73 Posted: Wed, May 20 2020, 3:54 PM EST
Joined: 11-23-2011
Posts: 28,788
teedubbya wrote:
Many in here alone


I know...sigh...

shaming will not work on those without shame
HockeyDad Offline
#74 Posted: Wed, May 20 2020, 4:23 PM EST
Joined: 09-20-2000
Posts: 46,134
He’s already locked up the election. The other candidate has Alzheimer’s.
fiddler898 Offline
#75 Posted: Wed, May 20 2020, 4:28 PM EST
Joined: 06-15-2009
Posts: 3,782
At least our potatoes are safe.
HockeyDad Offline
#76 Posted: Wed, May 20 2020, 4:30 PM EST
Joined: 09-20-2000
Posts: 46,134
The CDC just reported that potatoes can spread Covid to humans.
victor809 Offline
#77 Posted: Wed, May 20 2020, 4:37 PM EST
Joined: 10-14-2011
Posts: 23,866
HockeyDad wrote:
The CDC just reported that potatoes can spread Covid to humans.


No wonder twitler wanted armed guards around them
teedubbya Offline
#78 Posted: Wed, May 20 2020, 4:37 PM EST
Joined: 08-14-2003
Posts: 95,637
Only when inserted.

Poor drafter
DrafterX Offline
#79 Posted: Wed, May 20 2020, 4:57 PM EST
Joined: 10-18-2005
Posts: 98,551
Mellow
victor809 Offline
#80 Posted: Wed, May 20 2020, 7:02 PM EST
Joined: 10-14-2011
Posts: 23,866
teedubbya wrote:
Only when inserted.

Poor drafter


The armed guards? Or the guard's arms?

poor drafter.
victor809 Offline
#81 Posted: Wed, May 20 2020, 7:06 PM EST
Joined: 10-14-2011
Posts: 23,866
https://detroit.cbslocal.com/2020/05/20/how-can-i-be-sick-woman-who-took-hydroxychloroquine-for-19-years-to-treat-lupus-still-got-covid-19/

Well.... so it doesn't work as a preventative either... (not a study... just an amusing result)
delta1 Offline
#82 Posted: Wed, May 20 2020, 7:17 PM EST
Joined: 11-23-2011
Posts: 28,788
fool me once, shame on you...fool me twice, I got fooled again...
tailgater Offline
#83 Posted: Thu, May 21 2020, 10:27 AM EST
Joined: 06-01-2000
Posts: 26,185
HockeyDad wrote:
He’s already locked up the election. The other candidate has Alzheimer’s.


I hear it's better than Parkinsons.
tailgater Offline
#84 Posted: Thu, May 21 2020, 10:42 AM EST
Joined: 06-01-2000
Posts: 26,185
victor809 wrote:
Whitehouse Dr released a letter saying he is giving it to our Covidiot of a president.

https://www.cnn.com/2020/05/18/politics/trump-physician-on-hydroxychloroquine/index.html

Let's think about what sort of message this says.

Through his actions, Twitler is continuing to promote a drug which has been studied by actual scientists and Dr's and been found to have no value in treating COVID.

Additionally, through his actions, Twitler actively avoids wearing a mask in public and when interacting with people. Something which has been studied by actual scientists and Dr's and been found to have a small impact in reducing the spread of COVID.




Regarding the drug, your statement is misleading. Sure, some scientist have that conclusion. But many others conclude there is promise, and many studies are being conducted within the medical community and other countries are actively using it.

As for the mask?
Even Fauci and the CDC change their tune on a daily basis.

You're very quick to oppose Trump for no reason than Trump.

A lot of what's going on is still being learned. Yet you treat it like a firm consensus.

And don't misunderstand me here. I'm not saying Trumps tactics are the right thing to do.
But he is giving hope in a world where the media is selling fear.

teedubbya Offline
#85 Posted: Thu, May 21 2020, 12:02 PM EST
Joined: 08-14-2003
Posts: 95,637
Hydroxychloroquine/chloroquine — There are insufficient data thus far to know whether hydroxychloroquine or chloroquine has a role in treatment of COVID-19. For this reason, we strongly recommend that patients should be referred to a clinical trial whenever possible. In the United States, the FDA has issued an emergency use authorization to allow the use of these agents in adolescents or adults hospitalized for COVID-19 when participation in clinical trials is not feasible [54]. When a clinical trial is not available, we suggest not routinely using hydroxychloroquine or chloroquine given the lack of clear benefit from limited data and potential for toxicity. If drugs are used for COVID-19 outside a clinical trial, the Infectious Diseases Society of America (IDSA) encourages creation of a registry, when possible, to systematically evaluate their safety and efficacy [55].

Additionally, if hydroxychloroquine or chloroquine is used outside of a clinical trial, the potential for adverse effects should be carefully assessed. In particular, these agents can prolong the QT interval and should be avoided in patients with prolonged baseline QTc interval or on other agents that affect cardiac conduction, and otherwise should be used with close monitoring. The American College of Cardiology has suggested QTc monitoring parameters in this setting [56]. QTc monitoring in this setting is discussed in detail elsewhere. (See "Coronavirus disease 2019 (COVID-19): Arrhythmias and conduction system disease", section on 'Monitoring for QT prolongation'.)

Other risks (eg, retinopathy or cardiomyopathy) are primarily with longer-term use and higher cumulative doses, but should be a consideration when deciding to use these agents. Catastrophic outcomes have been reported with hydroxychloroquine or chloroquine overdose; no individual should use these medications without medical supervision [57,58]. (See "Antimalarial drugs in the treatment of rheumatic disease", section on 'Adverse effects'.)

Both chloroquine and hydroxychloroquine have been reported to inhibit SARS-CoV-2 in vitro, although hydroxychloroquine appears to have more potent antiviral activity [59]. Randomized trials evaluating their clinical use are underway. However, published clinical data on either of these agents are limited, have methodologic problems, and do not suggest a clear benefit [60-65]. In an open-label randomized trial of 150 hospitalized patients with mild to moderate COVID-19 (either no pneumonia or pneumonia without hypoxia), adding hydroxychloroquine to standard of care did not improve the rate of SARS-CoV-2 clearance (84 versus 81 percent with standard of care alone) or result in symptomatic improvement (60 versus 66 percent) by 28 days [64]. Methodologic concerns with this trial include concomitant co-therapies, baseline differences between the groups, and lack of blinding or placebo control.

Available evidence does not suggest a benefit for patients with severe COVID-19, although data in this population are limited to observational studies. In an observational study of nearly 1400 patients with COVID-19 admitted to a hospital in New York, hydroxychloroquine use was reported in 811 patients and was associated with a higher risk of intubation or death (hazard ratio [HR] 2.37) [62]. Patients who received hydroxychloroquine were older, were more likely to have comorbidities, and had more severe illness than those who did not, which were likely confounding variables; in a multivariate analysis comparing those patients with a propensity score-matched subset of 274 patients who did not receive hydroxychloroquine, there was no association between hydroxychloroquine use and intubation or death (adjusted HR 1.04). In another observational study from France of 180 patients with severe COVID-19 who required oxygen supplementation but not critical care, the rates of transfer to the intensive care unit or death were similar among those who did and did not receive hydroxychloroquine [65].

Studies have, however, highlighted the potential for toxicity of hydroxychloroquine or chloroquine. One trial comparing two doses of chloroquine for COVID-19 was stopped early because of a higher mortality rate in the high-dose group [66]. In an observational study in which 84 patients received hydroxychloroquine, 10 percent had electrocardiographic changes that prompted discontinuation [65]. QTc prolongation with hydroxychloroquine and chloroquine are discussed in detail elsewhere. (See "Coronavirus disease 2019 (COVID-19): Arrhythmias and conduction system disease", section on 'Patients receiving QT-prolonging treatments (eg, hydroxychloroquine, chloroquine, azithromycin, etc)'.)

The evidence on the combination of hydroxychloroquine and azithromycin is discussed elsewhere. (See 'Others' below.)


OTHERS

Azithromycin and hydroxychloroquine – We do not use azithromycin in combination with hydroxychloroquine for treating COVID-19. Use of the combination has been described in observational studies [60,63,81,82]. Although one study suggested the use of azithromycin in combination with hydroxychloroquine was associated with more rapid resolution of virus detection than hydroxychloroquine alone [60], this result should be interpreted with caution because of the small sample size, substantial methodologic concerns [83], and unclear biologic plausibility. Another small observational study in patients with more severe illness did not suggest rapid viral RNA clearance with the combination [81]. Furthermore, both azithromycin and hydroxychloroquine are associated with QTc prolongation, and combined use may potentiate this adverse effect. In a large observational study of patients hospitalized with COVID-19 in New York, the adjusted mortality rate among those who received azithromycin plus hydroxychloroquine was similar compared with those who received neither agent, but the rate of cardiac arrest was higher [63].



All of the studies are linked. Some may not be publicly available but can be had. I'm sort of familiar with the NY hospital experience :) This is geared towards treatment not politics. Throwing politics in doesn't compute. That is another issue.
tonygraz Offline
#86 Posted: Thu, May 21 2020, 12:26 PM EST
Joined: 08-11-2008
Posts: 20,253
What's with the "poor Drafter" talk. Are we gonna start a go fund Drafter page ?
teedubbya Offline
#87 Posted: Thu, May 21 2020, 12:28 PM EST
Joined: 08-14-2003
Posts: 95,637
I think you spelled go fvck drafter page wrong
tonygraz Offline
#88 Posted: Thu, May 21 2020, 12:33 PM EST
Joined: 08-11-2008
Posts: 20,253
Oops !
Sunoverbeach Offline
#89 Posted: Thu, May 21 2020, 4:02 PM EST
Joined: 08-11-2017
Posts: 14,665
Whether it may or may not be a viable treatment is a fairly moot when considering this is reported to be taken as s preventative measure. That's just dumb. I won't be undertaking chemo and radiation treatments to prevent cancer
tailgater Offline
#90 Posted: Fri, May 22 2020, 9:40 AM EST
Joined: 06-01-2000
Posts: 26,185
TW, I'm not doubting the info you posted. But you are purposely ignoring anything that contradicts it.

2 seconds on google yielded https://www.sciencedirect.com/science/article/pii/S1477893920302179
From the link:
"Conclusion
Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients."

Not saying it's true. Or whether this specific website is reliable.
But there is sufficient data to merit investigations as to WHY people are reporting positive results.
Maybe HCQ isn't the answer. Probably not (in my opinion). But if it's doing something positive with some patients, alone or in combination with other treatments, then it's worthy of discussion.

This opinion is not even mildly controversial.
Except, Trump.
tailgater Offline
#91 Posted: Fri, May 22 2020, 9:43 AM EST
Joined: 06-01-2000
Posts: 26,185
Sunoverbeach wrote:
Whether it may or may not be a viable treatment is a fairly moot when considering this is reported to be taken as s preventative measure. That's just dumb. I won't be undertaking chemo and radiation treatments to prevent cancer


Preemptive (to the symptoms). Not preventive to the virus itself.
Subtle difference, but important.
teedubbya Offline
#92 Posted: Fri, May 22 2020, 10:10 AM EST
Joined: 08-14-2003
Posts: 95,637
tailgater wrote:
TW, I'm not doubting the info you posted. But you are purposely ignoring anything that contradicts it.

2 seconds on google yielded https://www.sciencedirect.com/science/article/pii/S1477893920302179
From the link:
"Conclusion
Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients."

Not saying it's true. Or whether this specific website is reliable.
But there is sufficient data to merit investigations as to WHY people are reporting positive results.
Maybe HCQ isn't the answer. Probably not (in my opinion). But if it's doing something positive with some patients, alone or in combination with other treatments, then it's worthy of discussion.

This opinion is not even mildly controversial.
Except, Trump.




I'm not ignoring anything purposely or otherwise. The fact you can proclaim that and believe that is interesting.

All I did was cut and paste the peer reviewed advice many medical providers turn to rather than the great google machine. It is a comprehensive literature review of all pertinent studies, (including the one you linked) updated daily and is well documented/footed. It considers all published or soon to be published data. It is a wealth of information and I pasted not even the tip of the ice burg. It is used by clinicians to treat not by internet warriors to argue. I really don't think they are ignoring anything that could be useful in treatment, at least not intentionally. It is not a political source. I merely gave a glimpse into what actual medical providers are looking at and considering when treating.

You seem to be obsessed with the politics. I'm frustrated by them. This isn't theoretical to me. It is real. I don't have that luxury. When it comes to the disease IDGAF about the politics and Trump and said so. I am intentionally clear when I stray from the virus to the politics which I didn't do. I was really careful not to. You seem to not have that ability.

I am fortunate to have access (ok not fortunate I need it to work in some cases) to this source and use it for various disease states frequently. I thought I'd share the leading straight down the middle medical view. For some reason this is the only time anyone has ever considered it political or ignoring relevant info. I wonder why?




Edit. By the way the study you linked to was included, its issues discussed, and footed in what I had pasted. It was not ignored in any way.
Speyside Offline
#93 Posted: Fri, May 22 2020, 11:21 AM EST
Joined: 03-16-2015
Posts: 13,106
Because it's an inconvienient truth. A segment of people want to believe it works even though it doesn't. I tried to explain to someone that he needed better understanding on how a virus works. His response indicated that how a virus works is an inconvenient truth for him. It disproves what he wants to be the truth.
teedubbya Offline
#94 Posted: Fri, May 22 2020, 2:19 PM EST
Joined: 08-14-2003
Posts: 95,637
I'm not even saying it doesn't work. I just am saying the state of things at the moment. This is no time to disregard evidence based medicine.
DrMaddVibe Offline
#95 Posted: Fri, May 22 2020, 2:36 PM EST
Joined: 10-21-2000
Posts: 55,431
teedubbya wrote:
I'm not even saying it doesn't work. I just am saying the state of things at the moment. This is no time to disregard evidence based medicine.



Sure would be nice to have links to that.
teedubbya Offline
#96 Posted: Fri, May 22 2020, 2:38 PM EST
Joined: 08-14-2003
Posts: 95,637
DrMaddVibe wrote:
Sure would be nice to have links to that.


It sure is. But the sourcing is right in front of you. Here you go. This isn't internet warrioring or the google machine. It is much more in depth and practical to the field. The whole thing is peer reviewed.

The foot numbering didn't copy over. But everything in there is sourced. If reading it you want to know what any of the specific footed studies etc. are you can count or I'll cross reference for you. I doubt you are serious though. If you are, cool. Maybe it's a start to a new field for you.

And before you get a boner over any single source this is a literature review. I know you know the implications of that.


REFERENCES
World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).

Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html (Accessed on February 14, 2020).

World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance (Accessed on February 14, 2020).

National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ (Accessed on April 21, 2020).

ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection (Accessed on April 01, 2020).

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.

Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.

Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. Circulation 2020.

American College of Cardiology. Troponin and BNP Use in COVID-19. Cardiology 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 (Accessed on April 16, 2020).

Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18:1023.

https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation (Accessed on April 27, 2020).

https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19 (Accessed on April 27, 2020).

https://dgs-urgent.sante.gouv.fr/dgsurgent/inter/detailsMessageBuilder.do?id=30500&cmd=visualiserMessage (Accessed on March 19, 2020).

Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368:m1086.

European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19 (Accessed on March 19, 2020).

WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 https://www.who.int/publications-detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 (Accessed on April 21, 2020).

Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection, Updated February 12, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html (Accessed on February 14, 2020).

World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance: Patient management. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management (Accessed on February 02, 2020).

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395:473.

Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician (Accessed on March 18, 2020).

European Society of Hypertension. ESH Statement on COVID-19. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/ (Accessed on March 18, 2020).

International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/ (Accessed on March 18, 2020).

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (Accessed on March 18, 2020).

https://hypertension.ca/wp-content/uploads/2020/03/2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf (Accessed on March 18, 2020).

Kickbusch I, Leung G. Response to the emerging novel coronavirus outbreak. BMJ 2020; 368:m406.

Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio 2015; 6:e01120.

Joint GI society message: COVID-19 clinical insights for our community of gastroenterologists and gastroenterology care providers. https://www.gastro.org/press-release/joint-gi-society-message-covid-19-clinical-insights-for-our-community-of-gastroenterologists-and-gastroenterology-care-providers (Accessed on March 18, 2020).

The European League Against Rheumatism. EULAR Guidance for patients COVID-19 outbreak. https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm (Accessed on March 18, 2020).

The American Academy of Dermatology. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf (Accessed on March 18, 2020).

American College of Rheumatology. https://www.rheumatology.org/announcements (Accessed on March 18, 2020).

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269.

US FDA. Remdesivir letter of EUA. https://www.fda.gov/media/137564/download (Accessed on May 01, 2020).

https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 (Accessed on April 29, 2020).

Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020.

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19. https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19 (Accessed on April 29, 2020).

Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382:929.

Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020.

Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020.

US Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma (Accessed on April 08, 2020).

Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020.

Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117:9490.

Zeng QL, Yu ZJ, Gou JJ, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. J Infect Dis 2020.

FDA News Release: Coronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19. April 3, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19 (Accessed on April 06, 2020).

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.

Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033.

Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020.

Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 2020.

Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 2020; 4:1307.

Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020.

Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020.

Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020; 117:10970.

US Food and Drug Administration. https://www.fda.gov/media/136534/download (Accessed on March 30, 2020).

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (Accessed on April 13, 2020).

Simpson TF, Kovacs RJ, Steckler EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. Cardiology 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 (Accessed on March 30, 2020).

CDC Health Alert Network. Severe Illness Associated with Using Non-Pharmaceutical Chloroquine Phosphate to Prevent and Treat Coronavirus Disease 2019 (COVID-19). March 28, 2020. https://emergency.cdc.gov/han/2020/han00431.asp?deliveryName=USCDC_511-DM24285 (Accessed on March 28, 2020).

Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med 2001; 19:420.
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; :105949.

Chen J, Lui D, Lui L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University 2020.

Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020.

Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 2020.

Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369:m1849.

Mahevas M, Tran VT, Roumer M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020.

Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open 2020; 3:e208857.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:271.

Treon SP, Castillo J, Skarbnik AP, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood 2020.

https://www.sciencemag.org/news/2020/04/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus (Accessed on April 27, 2020).

McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis 2020; 7:ofaa105.

World Health Organization. COVID 19 Landscape of experimental treatments. https://www.who.int/publications-detail/covid-19-landscape-of-experimental-treatments (Accessed on April 29, 2020).

Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering 2020.

Chan JF, Yao Y, Yeung ML, et al. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis 2015; 212:1904.

Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606.

Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95:571.

Hung IF, Lung KC, Tso E, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020.

Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients. Lancet Rheumatol 2020.

Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020.

Pontali E, Volpi S, Antonucci G, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol 2020.

Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 2020; 24:4040.

Molina JM, Delaugerre C, Goff JL, et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Medecine et Maladies Infectieuses 2020.

Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020; :101738.

International Society of Antimicrobial Chemotherapy. Statement on IJAA paper. April 3, 2020. https://www.isac.world/news-and-publications/official-isac-statement (Accessed on April 08, 2020).

Groneberg DA, Poutanen SM, Low DE, et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005; 5:147.

Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science 2020. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments (Accessed on March 26, 2020).

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382:1787.

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.

https://www.amerisourcebergen.com/coronavirus-covid-19-information (Accessed on May 09, 2020).

Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020; 7:e314.

Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis 2020.

IDSA and HIVMA. COVID-19: Special Considerations for People Living with HIV. April 4, 2020. https://www.idsociety.org/globalassets/covid-19-special-considerations (Accessed on April 06, 2020).

United States Department of Health and Human Services. Interim Guidance for COVID-19 and Persons with HIV. https://aidsinfo.nih.gov/guidelines/html/8/covid-19-and-persons-with-hiv--interim-guidance-/554/interim-guidance-for-covid-19-and-persons-with-hiv (Accessed on March 24, 2020).
delta1 Offline
#97 Posted: Fri, May 22 2020, 2:47 PM EST
Joined: 11-23-2011
Posts: 28,788
lotta foreign BS studies that can't be trusted..this is Murica!


that's why Trump didn't have the US join the rest of the world's joint vaccine effort...
ZRX1200 Offline
#98 Posted: Thu, Jun 4 2020, 6:04 PM EST
Joined: 07-08-2007
Posts: 60,604
teedubbya wrote:
It sure is. But the sourcing is right in front of you. Here you go. This isn't internet warrioring or the google machine. It is much more in depth and practical to the field. The whole thing is peer reviewed.

The foot numbering didn't copy over. But everything in there is sourced. If reading it you want to know what any of the specific footed studies etc. are you can count or I'll cross reference for you. I doubt you are serious though. If you are, cool. Maybe it's a start to a new field for you.

And before you get a boner over any single source this is a literature review. I know you know the implications of that.


REFERENCES
World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).

Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html (Accessed on February 14, 2020).

World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance (Accessed on February 14, 2020).

National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ (Accessed on April 21, 2020).

ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection (Accessed on April 01, 2020).

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.

Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.

Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. Circulation 2020.

American College of Cardiology. Troponin and BNP Use in COVID-19. Cardiology 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 (Accessed on April 16, 2020).

Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18:1023.

https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation (Accessed on April 27, 2020).

https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19 (Accessed on April 27, 2020).

https://dgs-urgent.sante.gouv.fr/dgsurgent/inter/detailsMessageBuilder.do?id=30500&cmd=visualiserMessage (Accessed on March 19, 2020).

Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368:m1086.

European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19 (Accessed on March 19, 2020).

WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 https://www.who.int/publications-detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 (Accessed on April 21, 2020).

Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection, Updated February 12, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html (Accessed on February 14, 2020).

World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance: Patient management. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management (Accessed on February 02, 2020).

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395:473.

Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician (Accessed on March 18, 2020).

European Society of Hypertension. ESH Statement on COVID-19. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/ (Accessed on March 18, 2020).

International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/ (Accessed on March 18, 2020).

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (Accessed on March 18, 2020).

https://hypertension.ca/wp-content/uploads/2020/03/2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf (Accessed on March 18, 2020).

Kickbusch I, Leung G. Response to the emerging novel coronavirus outbreak. BMJ 2020; 368:m406.

Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio 2015; 6:e01120.

Joint GI society message: COVID-19 clinical insights for our community of gastroenterologists and gastroenterology care providers. https://www.gastro.org/press-release/joint-gi-society-message-covid-19-clinical-insights-for-our-community-of-gastroenterologists-and-gastroenterology-care-providers (Accessed on March 18, 2020).

The European League Against Rheumatism. EULAR Guidance for patients COVID-19 outbreak. https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm (Accessed on March 18, 2020).

The American Academy of Dermatology. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf (Accessed on March 18, 2020).

American College of Rheumatology. https://www.rheumatology.org/announcements (Accessed on March 18, 2020).

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269.

US FDA. Remdesivir letter of EUA. https://www.fda.gov/media/137564/download (Accessed on May 01, 2020).

https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 (Accessed on April 29, 2020).

Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020.

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19. https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19 (Accessed on April 29, 2020).

Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382:929.

Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020.

Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020.

US Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma (Accessed on April 08, 2020).

Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020.

Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117:9490.

Zeng QL, Yu ZJ, Gou JJ, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. J Infect Dis 2020.

FDA News Release: Coronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19. April 3, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19 (Accessed on April 06, 2020).

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.

Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033.

Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020.

Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 2020.

Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 2020; 4:1307.

Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020.

Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020.

Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020; 117:10970.

US Food and Drug Administration. https://www.fda.gov/media/136534/download (Accessed on March 30, 2020).

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (Accessed on April 13, 2020).

Simpson TF, Kovacs RJ, Steckler EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. Cardiology 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 (Accessed on March 30, 2020).

CDC Health Alert Network. Severe Illness Associated with Using Non-Pharmaceutical Chloroquine Phosphate to Prevent and Treat Coronavirus Disease 2019 (COVID-19). March 28, 2020. https://emergency.cdc.gov/han/2020/han00431.asp?deliveryName=USCDC_511-DM24285 (Accessed on March 28, 2020).

Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med 2001; 19:420.
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; :105949.

Chen J, Lui D, Lui L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University 2020.

Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020.

Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 2020.

Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369:m1849.

Mahevas M, Tran VT, Roumer M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020.

Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open 2020; 3:e208857.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:271.

Treon SP, Castillo J, Skarbnik AP, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood 2020.

https://www.sciencemag.org/news/2020/04/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus (Accessed on April 27, 2020).

McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis 2020; 7:ofaa105.

World Health Organization. COVID 19 Landscape of experimental treatments. https://www.who.int/publications-detail/covid-19-landscape-of-experimental-treatments (Accessed on April 29, 2020).

Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering 2020.

Chan JF, Yao Y, Yeung ML, et al. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis 2015; 212:1904.

Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606.

Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95:571.

Hung IF, Lung KC, Tso E, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020.

Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients. Lancet Rheumatol 2020.

Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020.

Pontali E, Volpi S, Antonucci G, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol 2020.

Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 2020; 24:4040.

Molina JM, Delaugerre C, Goff JL, et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Medecine et Maladies Infectieuses 2020.

Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020; :101738.

International Society of Antimicrobial Chemotherapy. Statement on IJAA paper. April 3, 2020. https://www.isac.world/news-and-publications/official-isac-statement (Accessed on April 08, 2020).

Groneberg DA, Poutanen SM, Low DE, et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005; 5:147.

Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science 2020. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments (Accessed on March 26, 2020).

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382:1787.

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.

https://www.amerisourcebergen.com/coronavirus-covid-19-information (Accessed on May 09, 2020).

Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020; 7:e314.

Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis 2020.

IDSA and HIVMA. COVID-19: Special Considerations for People Living with HIV. April 4, 2020. https://www.idsociety.org/globalassets/covid-19-special-considerations (Accessed on April 06, 2020).

United States Department of Health and Human Services. Interim Guidance for COVID-19 and Persons with HIV. https://aidsinfo.nih.gov/guidelines/html/8/covid-19-and-persons-with-hiv--interim-guidance-/554/interim-guidance-for-covid-19-and-persons-with-hiv (Accessed on March 24, 2020).



https://retractionwatch.com/2020/06/02/nejm-places-expression-of-concern-on-controversial-study-of-drugs-for-covid-19/
delta1 Offline
#99 Posted: Thu, Jun 4 2020, 6:08 PM EST
Joined: 11-23-2011
Posts: 28,788
what about the VA study? that was legit, wasn't it?
HockeyDad Offline
#100 Posted: Thu, Jun 4 2020, 6:51 PM EST
Joined: 09-20-2000
Posts: 46,134
I would need to know the results before I could say if it were legit.
Users browsing this topic
Guest
6 Pages<123456>
Back to Top